WebHeader_Grove.png
Play Live Radio
Next Up:
0:00
0:00
Available On Air Stations
Get 2 limited-edition podcast mugs when you make a sustaining gift of $8 or more per month today!

N.H. Part of Nationwide Settlement Against Boehringer Ingelheim Pharmaceuticals

Siedziba_Boehringer_Ingelheim_w_Polsce.JPG
Wikimedia Commons
/

New Hampshire will get about $144,000 as part of a nationwide, multimillion-dollar settlement against a company accused of off-label marketing for four of its drugs.

All 50 states participated in the $13.5 million settlement against Boehringer Ingelheim Pharmaceuticals, or BIPI. The states claimed BIPI misrepresented the benefits of four specialty prescription drugs approved to treat ailments ranging from metabolic syndrome to platelet conditions: Micardis, Aggrenox, Atrovent and Combivent.

Senior Assistant Attorney General Jim Boffetti, who leads New Hampshire’s consumer protection unit, says the money the state gets from this settlement will likely go back to funding work on future consumer protection cases.

“This office and I think all attorneys general offices take the marketing of prescription drugs and especially allegations of deceptive marketing very seriously,” Boffetti said.

Under the terms of the settlement, the company also agreed to rein in financial incentives for any off-label uses of the drugs and to limit sampling of the drugs only to providers who treat conditions that line up with how the products are labeled.

Casey McDermott is a senior news editor at New Hampshire Public Radio. Throughout her time as an NHPR reporter and editor, she has worked with colleagues across the newsroom to deepen the station’s accountability coverage, data journalism and audience engagement across platforms.

You make NHPR possible.

NHPR is nonprofit and independent. We rely on readers like you to support the local, national, and international coverage on this website. Your support makes this news available to everyone.

Give today. A monthly donation of $5 makes a real difference.